{"id":"https://openalex.org/W7204707698","doi":"https://doi.org/10.1016/s2152-2650(26)03071-5","title":"MM-1573: Thirty-Day Nonrelapse Mortality In Multiple Myeloma Patients Treated With Bispecific T-cell Engagers: A Fear Analysis","display_name":"MM-1573: Thirty-Day Nonrelapse Mortality In Multiple Myeloma Patients Treated With Bispecific T-cell Engagers: A Fear Analysis","publication_year":2026,"publication_date":"2026-08-01","ids":{"openalex":"https://openalex.org/W7204707698","doi":"https://doi.org/10.1016/s2152-2650(26)03071-5"},"language":"en","primary_location":{"id":"doi:10.1016/s2152-2650(26)03071-5","doi":"https://doi.org/10.1016/s2152-2650(26)03071-5","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)03071-5","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2669","issn":["2152-2669","2152-2650"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W7204707698"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5135240254","display_name":"Elias Tayar","orcid":"https://orcid.org/0000-0001-9343-3400","observed_orcids":["https://orcid.org/0000-0001-9343-3400"]},"institutions":[{"id":"https://openalex.org/I44461941","display_name":"University of Houston","ror":"https://ror.org/048sx0r50","country_code":"US","type":"education","lineage":["https://openalex.org/I44461941"]},{"id":"https://openalex.org/I52913039","display_name":"University of Houston - Clear Lake","ror":"https://ror.org/01t817z14","country_code":"US","type":"education","lineage":["https://openalex.org/I52913039"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elias Tayar","raw_affiliation_strings":["University of Houston/HCA Healthcare Clear Lake, Webster, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Houston/HCA Healthcare Clear Lake, Webster, TX, USA","institution_ids":["https://openalex.org/I44461941","https://openalex.org/I52913039"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148758688","display_name":"Samip Master","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800124591","display_name":"Texas Oncology","ror":"https://ror.org/02ketev28","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800124591"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Samip Master","raw_affiliation_strings":["Texas Oncology, Webster, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Texas Oncology, Webster, TX, USA","institution_ids":["https://openalex.org/I2800124591"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5148651586","display_name":"Rammurti Kamble","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800124591","display_name":"Texas Oncology","ror":"https://ror.org/02ketev28","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800124591"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rammurti Kamble","raw_affiliation_strings":["Texas Oncology, Webster, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Texas Oncology, Webster, TX, USA","institution_ids":["https://openalex.org/I2800124591"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3890,"currency":"USD","value_usd":3890},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":null,"first_page":"S1194","last_page":"S1195"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.006200000178068876,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.8500000238418579},{"id":"https://openalex.org/keywords/bispecific-t-cell-engagers","display_name":"bispecific T-cell engagers","score":0.9990000128746033},{"id":"https://openalex.org/keywords/treatment-related-mortality","display_name":"non-relapse mortality","score":0.9900000095367432},{"id":"https://openalex.org/keywords/teclistamab","display_name":"teclistamab","score":0.8330000042915344},{"id":"https://openalex.org/keywords/elranatamab","display_name":"elranatamab","score":0.968999981880188},{"id":"https://openalex.org/keywords/talquetamab","display_name":"talquetamab","score":1.0},{"id":"https://openalex.org/keywords/b-cell-maturation-antigen","display_name":"BCMA","score":0.7639999985694885},{"id":"https://openalex.org/keywords/gprc5d","display_name":"GPRC5D","score":0.8619999885559082},{"id":"https://openalex.org/keywords/cytokine-release-syndrome","display_name":"cytokine release syndrome","score":0.7570000290870667},{"id":"https://openalex.org/keywords/immune-effector-cell-associated-neurotoxicity-syndrome","display_name":"immune effector cell-associated neurotoxicity syndrome","score":0.9539999961853027},{"id":"https://openalex.org/keywords/sepsis","display_name":"sepsis","score":0.7649999856948853},{"id":"https://openalex.org/keywords/pneumonia","display_name":"pneumonia","score":0.4259999990463257},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.6430000066757202},{"id":"https://openalex.org/keywords/adverse-event-reporting","display_name":"adverse event reporting","score":0.5529999732971191}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9753999710083008},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7774999737739563},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7192000150680542},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6625000238418579},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.28130000829696655},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.26330000162124634},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.2524000108242035},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.25209999084472656},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2231999933719635},{"id":"https://openalex.org/C3020493868","wikidata":"https://www.wikidata.org/wiki/Q55631277","display_name":"Real world data","level":2,"score":0.20010000467300415}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s2152-2650(26)03071-5","doi":"https://doi.org/10.1016/s2152-2650(26)03071-5","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)03071-5","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2669","issn":["2152-2669","2152-2650"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7127389583","https://openalex.org/W4404734138","https://openalex.org/W7204722394","https://openalex.org/W4413775237","https://openalex.org/W4399480650","https://openalex.org/W4417069340","https://openalex.org/W7108463040","https://openalex.org/W7204733707","https://openalex.org/W7162533122","https://openalex.org/W3170440921"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2026-08-31T00:00:00"}